Clinical and biomarker results from a phase II trial of combined cabozantinib and durvalumab in patients with chemotherapy-refractory colorectal cancer (CRC): CAMILLA CRC cohort.
Journal
Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555
Informations de publication
Date de publication:
20 Feb 2024
20 Feb 2024
Historique:
received:
17
10
2023
accepted:
31
01
2024
medline:
21
2
2024
pubmed:
21
2
2024
entrez:
20
2
2024
Statut:
epublish
Résumé
CAMILLA is a basket trial (NCT03539822) evaluating cabozantinib plus the ICI durvalumab in chemorefractory gastrointestinal cancer. Herein, are the phase II colorectal cohort results. 29 patients were evaluable. 100% had confirmed pMMR/MSS tumors. Primary endpoint was met with ORR of 27.6% (95% CI 12.7-47.2%). Secondary endpoints of 4-month PFS rate was 44.83% (95% CI 26.5-64.3%); and median OS was 9.1 months (95% CI 5.8-20.2). Grade≥3 TRAE occurred in 39%. In post-hoc analysis of patients with RAS wild type tumors, ORR was 50% and median PFS and OS were 6.3 and 21.5 months respectively. Exploratory spatial transcriptomic profiling of pretreatment tumors showed upregulation of VEGF and MET signaling, increased extracellular matrix activity and preexisting anti-tumor immune responses coexisting with immune suppressive features like T cell migration barriers in responders versus non-responders. Cabozantinib plus durvalumab demonstrated anti-tumor activity, manageable toxicity, and have led to the activation of the phase III STELLAR-303 trial.
Identifiants
pubmed: 38378868
doi: 10.1038/s41467-024-45960-2
pii: 10.1038/s41467-024-45960-2
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1533Informations de copyright
© 2024. The Author(s).
Références
Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71, 209–249 (2021).
pubmed: 33538338
doi: 10.3322/caac.21660
Diaz, L. A. Jr et al. Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study. Lancet Oncol. 23, 659–670 (2022).
pubmed: 35427471
pmcid: 9533375
doi: 10.1016/S1470-2045(22)00197-8
André, T. et al. Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142. Ann. Oncol. 33, 1052–1060 (2022).
pubmed: 35764271
doi: 10.1016/j.annonc.2022.06.008
Khambata-Ford, S. et al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J. Clin. Oncol. 25, 3230–3237 (2007).
pubmed: 17664471
doi: 10.1200/JCO.2006.10.5437
Prager, G. W. et al. Trifluridine–tipiracil and bevacizumab in refractory metastatic colorectal cancer. N. Engl. J. Med. 388, 1657–1667 (2023).
pubmed: 37133585
doi: 10.1056/NEJMoa2214963
Grothey, A. et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381, 303–312 (2013).
pubmed: 23177514
doi: 10.1016/S0140-6736(12)61900-X
Kwilas, A. R., Ardiani, A., Donahue, R. N., Aftab, D. T. & Hodge, J. W. Dual effects of a targeted small-molecule inhibitor (cabozantinib) on immune-mediated killing of tumor cells and immune tumor microenvironment permissiveness when combined with a cancer vaccine. J. Transl. Med. 12, 294 (2014).
pubmed: 25388653
pmcid: 4236498
doi: 10.1186/s12967-014-0294-y
Patnaik, A. et al. Cabozantinib eradicates advanced murine prostate cancer by activating antitumor innate immunity. Cancer Discov. 7, 750–765 (2017).
pubmed: 28274958
pmcid: 5501767
doi: 10.1158/2159-8290.CD-16-0778
Lu, X. et al. Effective combinatorial immunotherapy for castration-resistant prostate cancer. Nature 543, 728–732 (2017).
pubmed: 28321130
pmcid: 5374023
doi: 10.1038/nature21676
Liu, H. et al. Tyrosine kinase inhibitor cabozantinib inhibits murine renal cancer by activating innate and adaptive immunity. Front Oncol. 11, 663517 (2021).
pubmed: 33954115
pmcid: 8089383
doi: 10.3389/fonc.2021.663517
Ho, W. J. et al. Neoadjuvant cabozantinib and nivolumab convert locally advanced hepatocellular carcinoma into resectable disease with enhanced antitumor immunity. Nat. Cancer 2, 891–903 (2021).
pubmed: 34796337
pmcid: 8594857
doi: 10.1038/s43018-021-00234-4
Lang, J. et al. Cabozantinib sensitizes microsatellite stable colorectal cancer to immune checkpoint blockade by immune modulation in human immune system mouse models. Front Oncol. 12, 877635 (2022).
pubmed: 36419897
pmcid: 9676436
doi: 10.3389/fonc.2022.877635
Scott, A. J. et al. A phase II study investigating cabozantinib in patients with refractory metastatic colorectal cancer (AGICC 17CRC01). Cancer Res. Commun. 2, 1188–1196 (2022).
pubmed: 36969746
pmcid: 10035393
doi: 10.1158/2767-9764.CRC-22-0169
Yau, T. et al. Nivolumab Plus Cabozantinib With or Without Ipilimumab for Advanced Hepatocellular Carcinoma: Results From Cohort 6 of the CheckMate 040 Trial. J Clin Oncol. 41 1747–1757 (2020).
Apolo, A. B. et al. Phase I study of cabozantinib and nivolumab alone or with ipilimumab for advanced or metastatic urothelial carcinoma and other genitourinary tumors. J Clin Oncol. 38, 3672–3684 (2020).
Keeler, M. E. et al. Pembrolizumab (pembro) and cabozantinib (cabo) in patients (pts) with metastatic renal cell carcinoma (mRCC): Phase I results. J. Clin. Oncol. 37, 600–600 (2019).
doi: 10.1200/JCO.2019.37.7_suppl.600
Choueiri, T. K. et al. Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma. N. Engl. J. Med. 384, 829–841 (2021).
pubmed: 33657295
pmcid: 8436591
doi: 10.1056/NEJMoa2026982
Agarwal, N. et al. Cabozantinib in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer: Results of cohort 6 of the COSMIC-021 study. J. Clin. Oncol. 38, 5564–5564 (2020).
doi: 10.1200/JCO.2020.38.15_suppl.5564
Neal, J. W. et al. Cabozantinib in combination with atezolizumab in non-small cell lung cancer (NSCLC) patients previously treated with an immune checkpoint inhibitor: Results from cohort 7 of the COSMIC-021 study. J. Clin. Oncol. 38, 9610–9610 (2020).
doi: 10.1200/JCO.2020.38.15_suppl.9610
Pal, S. K. et al. Cabozantinib in combination with atezolizumab in urothelial carcinoma previously treated with platinum-containing chemotherapy: Results from cohort 2 of the COSMIC-021 study. J. Clin. Oncol. 38, 5013–5013 (2020).
doi: 10.1200/JCO.2020.38.15_suppl.5013
Saeed, A. et al. Cabozantinib plus durvalumab in advanced gastroesophageal cancer and other gastrointestinal malignancies: Phase Ib CAMILLA trial results. Cell Rep. Med. 4, 100916 (2023).
pubmed: 36702123
pmcid: 9975105
doi: 10.1016/j.xcrm.2023.100916
van Loon, K., Huijbers, E. J. M. & Griffioen, A. W. Secreted frizzled-related protein 2: a key player in noncanonical Wnt signaling and tumor angiogenesis. Cancer Metastasis Rev. 40, 191–203 (2021).
pubmed: 33140138
doi: 10.1007/s10555-020-09941-3
Zhang, Z. et al. Functional and clinical characteristics of focal adhesion kinases in cancer progression. Front. Cell Dev. Biol. 10, 1040311 (2022).
pubmed: 36407100
pmcid: 9666724
doi: 10.3389/fcell.2022.1040311
Deshmukh, A. P. et al. Identification of EMT signaling cross-talk and gene regulatory networks by single-cell RNA sequencing. Proc. Natl Acad. Sci. USA 118, e2102050118 (2021).
pubmed: 33941680
pmcid: 8126782
doi: 10.1073/pnas.2102050118
Jackstadt, R. et al. Epithelial NOTCH signaling rewires the tumor microenvironment of colorectal cancer to drive poor-prognosis subtypes and metastasis. Cancer Cell 36, 319–336.e317 (2019).
pubmed: 31526760
pmcid: 6853173
doi: 10.1016/j.ccell.2019.08.003
Zhao, H. et al. Wnt signaling in colorectal cancer: pathogenic role and therapeutic target. Mol. Cancer 21, 144 (2022).
pubmed: 35836256
pmcid: 9281132
doi: 10.1186/s12943-022-01616-7
Gonzalez, D. M. & Medici, D. Signaling mechanisms of the epithelial-mesenchymal transition. Sci. Signal 7, re8 (2014).
pubmed: 25249658
pmcid: 4372086
doi: 10.1126/scisignal.2005189
Janiszewska, M., Primi, M. C. & Izard, T. Cell adhesion in cancer: Beyond the migration of single cells. J. Biol. Chem. 295, 2495–2505 (2020).
pubmed: 31937589
pmcid: 7039572
doi: 10.1074/jbc.REV119.007759
Ayers, M. et al. IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade. J. Clin. Investig. 127, 2930–2940 (2017).
pubmed: 28650338
pmcid: 5531419
doi: 10.1172/JCI91190
Schwaab, T., Weiss, J. E., Schned, A. R. & Barth, R. J. Jr Dendritic cell infiltration in colon cancer. J. Immunother. 24, 130–137 (2001).
pubmed: 11449069
doi: 10.1097/00002371-200103000-00007
Gulubova, M. et al. Relationship of TGF-β1 and Smad7 expression with decreased dendritic cell infiltration in liver gastrointestinal cancer metastasis. Apmis 121, 967–975 (2013).
pubmed: 23998914
doi: 10.1111/apm.12096
Chen, E. X. et al. Effect of combined immune checkpoint inhibition vs best supportive care alone in patients with advanced colorectal cancer: the Canadian Cancer Trials Group CO.26 Study. JAMA Oncol. 6, 831–838 (2020).
pubmed: 32379280
doi: 10.1001/jamaoncol.2020.0910
Patel, M. R., Falchook, G. S., Hamada, K., Makris, L. & Bendell, J. C. A phase 2 trial of trifluridine/tipiracil plus nivolumab in patients with heavily pretreated microsatellite-stable metastatic colorectal cancer. Cancer Med. 10, 1183–1190 (2021).
pubmed: 33544407
pmcid: 7926002
doi: 10.1002/cam4.3630
Mettu, N. B. et al. Assessment of capecitabine and bevacizumab with or without atezolizumab for the treatment of refractory metastatic colorectal cancer: a randomized clinical trial. JAMA Netw. Open 5, e2149040–e2149040 (2022).
pubmed: 35179586
pmcid: 8857687
doi: 10.1001/jamanetworkopen.2021.49040
Martinelli, E. et al. Cetuximab rechallenge plus avelumab in pretreated patients with RAS wild-type metastatic colorectal cancer: the phase 2 single-arm clinical CAVE trial. JAMA Oncol. 7, 1529–1535 (2021).
pubmed: 34382998
doi: 10.1001/jamaoncol.2021.2915
Fukuoka, S. et al. Regorafenib plus nivolumab in patients with advanced gastric or colorectal cancer: an open-label, dose-escalation, and dose-expansion phase Ib trial (REGONIVO, EPOC1603). J. Clin. Oncol. 38, 2053–2061 (2020).
pubmed: 32343640
doi: 10.1200/JCO.19.03296
Cousin, S. et al. Regorafenib-avelumab combination in patients with microsatellite stable colorectal cancer (REGOMUNE): a single-arm, open-label, Phase II Trial. Clin. Cancer Res. 27, 2139–2147 (2021).
pubmed: 33495314
doi: 10.1158/1078-0432.CCR-20-3416
Barzi, A. et al. Phase I/II study of regorafenib (rego) and pembrolizumab (pembro) in refractory microsatellite stable colorectal cancer (MSSCRC). J. Clin. Oncol. 40, 15–15 (2022).
doi: 10.1200/JCO.2022.40.4_suppl.015
Kim, R. D. et al. A phase I/Ib study of regorafenib and nivolumab in mismatch repair proficient advanced refractory colorectal cancer. Eur. J. Cancer 169, 93–102 (2022).
pubmed: 35526308
doi: 10.1016/j.ejca.2022.03.026
Wang, F. et al. Regorafenib plus toripalimab in patients with metastatic colorectal cancer: a phase Ib/II clinical trial and gut microbiome analysis. Cell Rep. Med. 2, 100383 (2021).
pubmed: 34622226
pmcid: 8484502
doi: 10.1016/j.xcrm.2021.100383
Fakih, M. et al. Regorafenib plus nivolumab in patients with mismatch repair-proficient/microsatellite stable metastatic colorectal cancer: a single-arm, open-label, multicentre phase 2 study. eClinicalMedicine 58, 101917 (2023).
pubmed: 37090438
pmcid: 10119887
doi: 10.1016/j.eclinm.2023.101917
Eng, C. et al. Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial. Lancet Oncol. 20, 849–861 (2019).
pubmed: 31003911
doi: 10.1016/S1470-2045(19)30027-0
Lieu, C. H. et al. Results from the safety lead-in for a phase II study of pembrolizumab in combination with binimetinib and bevacizumab in patients with refractory metastatic colorectal cancer (mCRC). J. Clin. Oncol. 38, 4031–4031 (2020).
doi: 10.1200/JCO.2020.38.15_suppl.4031
Johnson, B. et al. Phase II study of durvalumab (anti-PD-L1) and trametinib (MEKi) in microsatellite stable (MSS) metastatic colorectal cancer (mCRC). J. Immunother. Cancer 10, e005332 (2022).
pubmed: 36007963
pmcid: 9422817
doi: 10.1136/jitc-2022-005332
Merck. Merck and Eisai Provide Update on Phase 3 Trials of KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) In Certain Patients With Advanced Melanoma (LEAP-003) and Metastatic Colorectal Cancer (LEAP-017) https://www.merck.com/news/merck-and-eisai-provide-update-on-phase-3-leap-001-trial-evaluating-pembrolizumab-plus-lenvima-lenvatinib-as-first-line-treatment-for-patients-with-advanced-or-recurrent-endometrial-carcinom/ (2023).
Santoni, M. et al. Antitumor effects of the multi-target tyrosine kinase inhibitor cabozantinib: a comprehensive review of the preclinical evidence. Expert Rev. Anticancer Ther. 21, 1029–1054 (2021).
pubmed: 34445927
doi: 10.1080/14737140.2021.1919090
Scirocchi, F. et al. Immunogenic cell death and immunomodulatory effects of cabozantinib. Front. Oncol. 11, 755433 (2021).
pubmed: 34745989
pmcid: 8564482
doi: 10.3389/fonc.2021.755433
El-Khoueiry, A. B. et al. Results from a phase 1a/1b study of botensilimab (BOT), a novel innate/adaptive immune activator, plus balstilimab (BAL; anti-PD-1 antibody) in metastatic heavily pretreated microsatellite stable colorectal cancer (MSS CRC). J. Clin. Oncol. 41, LBA8–LBA8 (2023).
doi: 10.1200/JCO.2023.41.4_suppl.LBA8
Lee, James et al. Regulatory T cell control of systemic immunity and immunotherapy response in liver metastasis. Sci. Immunol. 5, eaba0759 (2020).
pubmed: 33008914
pmcid: 7755924
doi: 10.1126/sciimmunol.aba0759
Yu, J. et al. Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination. Nat. Med. 27, 152–164 (2021).
pubmed: 33398162
pmcid: 8095049
doi: 10.1038/s41591-020-1131-x
Yang, S. et al. Integrated multi-omics landscape of liver metastases. Gastroenterology 164, 407–423.e417 (2023).
pubmed: 36574521
doi: 10.1053/j.gastro.2022.11.029
Abrams, T. A. et al. A phase 1b multitumor cohort study of cabozantinib plus atezolizumab in advanced solid tumors (COSMIC-021): Results of the colorectal cancer cohort. J. Clin. Oncol. 40, 121–121 (2022).
doi: 10.1200/JCO.2022.40.4_suppl.121
Kim, R. D. et al. Pembrolizumab (pembro) plus mFOLFOX7 or FOLFIRI for metastatic colorectal cancer (CRC) in KEYNOTE-651: Long-term follow-up of cohorts B and D. J. Clin. Oncol. 40, 3521–3521 (2022).
doi: 10.1200/JCO.2022.40.16_suppl.3521
André, T. et al. Pembrolizumab in microsatellite-instability–high advanced colorectal cancer. N. Engl. J. Med. 383, 2207–2218 (2020).
pubmed: 33264544
doi: 10.1056/NEJMoa2017699
Liao, W. et al. KRAS-IRF2 axis drives immune suppression and immune therapy resistance in colorectal cancer. Cancer Cell 35, 559–572.e557 (2019).
pubmed: 30905761
pmcid: 6467776
doi: 10.1016/j.ccell.2019.02.008
Mitra, A. K. et al. Ligand-independent activation of c-Met by fibronectin and alpha(5)beta(1)-integrin regulates ovarian cancer invasion and metastasis. Oncogene 30, 1566–1576 (2011).
pubmed: 21119598
doi: 10.1038/onc.2010.532
Hui, A. Y. et al. Src and FAK mediate cell-matrix adhesion-dependent activation of Met during transformation of breast epithelial cells. J. Cell Biochem 107, 1168–1181 (2009).
pubmed: 19533669
doi: 10.1002/jcb.22219
Mitra, S. K. & Schlaepfer, D. D. Integrin-regulated FAK-Src signaling in normal and cancer cells. Curr. Opin. Cell Biol. 18, 516–523 (2006).
pubmed: 16919435
doi: 10.1016/j.ceb.2006.08.011
Cooper, J. & Giancotti, F. G. Integrin signaling in cancer: mechanotransduction, stemness, epithelial plasticity, and therapeutic resistance. Cancer Cell 35, 347–367 (2019).
pubmed: 30889378
pmcid: 6684107
doi: 10.1016/j.ccell.2019.01.007
Stanislovas, J. & Kermorgant, S. c-Met-integrin cooperation: mechanisms, tumorigenic effects, and therapeutic relevance. Front Cell Dev. Biol. 10, 994528 (2022).
pubmed: 36330337
pmcid: 9624249
doi: 10.3389/fcell.2022.994528
Zhou, J., Ji, Q. & Li, Q. Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies. J. Exp. Clin. Cancer Res. 40, 328 (2021).
pubmed: 34663410
pmcid: 8522158
doi: 10.1186/s13046-021-02130-2
Cruz da Silva, E., Dontenwill, M., Choulier, L. & Lehmann, M. Role of integrins in resistance to therapies targeting growth factor receptors in cancer. Cancers 11, 692 (2019).
pubmed: 31109009
pmcid: 6562376
doi: 10.3390/cancers11050692
Ju, L. & Zhou, C. Association of integrin beta1 and c-MET in mediating EGFR TKI gefitinib resistance in non-small cell lung cancer. Cancer Cell Int. 13, 15 (2013).
pubmed: 23402326
pmcid: 3583715
doi: 10.1186/1475-2867-13-15
Salmon, H. et al. Matrix architecture defines the preferential localization and migration of T cells into the stroma of human lung tumors. J. Clin. Investig. 122, 899–910 (2012).
pubmed: 22293174
pmcid: 3287213
doi: 10.1172/JCI45817
Chen, D. S. & Mellman, I. Elements of cancer immunity and the cancer-immune set point. Nature 541, 321–330 (2017).
pubmed: 28102259
doi: 10.1038/nature21349
Hecht, J. R. et al. STELLAR-303: A phase 3 study of XL092 in combination with atezolizumab versus regorafenib in patients with previously treated metastatic colorectal cancer (mCRC). J. Clin. Oncol. 41, TPS267–TPS267 (2023).
doi: 10.1200/JCO.2023.41.4_suppl.TPS267
Fisher, N. C. et al. Biological misinterpretation of transcriptional signatures in tumor samples can unknowingly undermine mechanistic understanding and faithful alignment with preclinical data. Clin. Cancer Res. 28, 4056–4069 (2022).
pubmed: 35792866
pmcid: 9475248
doi: 10.1158/1078-0432.CCR-22-1102
Beechem, J. M. High-plex spatially resolved RNA and protein detection using digital spatial profiling: a technology designed for immuno-oncology biomarker discovery and translational research. Methods Mol. Biol. 2055, 563–583 (2020).
pubmed: 31502169
doi: 10.1007/978-1-4939-9773-2_25
Bergholtz, H. et al. Best practices for spatial profiling for breast cancer research with the GeoMx((R)) digital spatial profiler. Cancers 13, 4456 (2021).
pubmed: 34503266
pmcid: 8431590
doi: 10.3390/cancers13174456
Decalf, J., Albert, M. L. & Ziai, J. New tools for pathology: a user’s review of a highly multiplexed method for in situ analysis of protein and RNA expression in tissue. J. Pathol. 247, 650–661 (2019).
pubmed: 30570141
doi: 10.1002/path.5223
Jung, M. et al. Intratumoral spatial heterogeneity of tumor-infiltrating lymphocytes is a significant factor for precisely stratifying prognostic immune subgroups of microsatellite instability-high colorectal carcinomas. Mod. Pathol. 35, 2011–2022 (2022).
pubmed: 35869301
doi: 10.1038/s41379-022-01137-0
Pelka, K. et al. Spatially organized multicellular immune hubs in human colorectal cancer. Cell 184, 4734–4752.e4720 (2021).
pubmed: 34450029
pmcid: 8772395
doi: 10.1016/j.cell.2021.08.003
Roelands, J. et al. Transcriptomic and immunophenotypic profiling reveals molecular and immunological hallmarks of colorectal cancer tumourigenesis. Gut 72 1326–1339(2022).
Wang, N., Li, X., Wang, R. & Ding, Z. Spatial transcriptomics and proteomics technologies for deconvoluting the tumor microenvironment. Biotechnol. J. 16, e2100041 (2021).
pubmed: 34125481
doi: 10.1002/biot.202100041
Wang, N. et al. Tumor microenvironment profiles reveal distinct therapy-oriented proteogenomic characteristics in colorectal cancer. Front. Bioeng. Biotechnol. 9, 757378 (2021).
pubmed: 34778231
pmcid: 8581216
doi: 10.3389/fbioe.2021.757378
Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).
pubmed: 25516281
pmcid: 4302049
doi: 10.1186/s13059-014-0550-8
Wu, T. et al. clusterProfiler 4.0: A universal enrichment tool for interpreting omics data. Innovation 2, 100141 (2021).
pubmed: 34557778
pmcid: 8454663
Wickham, H. ggplot2: Elegant Graphics for Data Analysis (Springer-Verlag, New York, 2016).
Hänzelmann, S., Castelo, R. & Guinney, J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinform. 14, 7 (2013).
doi: 10.1186/1471-2105-14-7
Ritchie, M. E. et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 43, e47 (2015).
pubmed: 25605792
pmcid: 4402510
doi: 10.1093/nar/gkv007
Kyung, M., Gill, J., Ghosh, M. & Casella, G. Penalized regression, standard errors, and bayesian lassos. Bayesian Anal. 5, 369–412 (2010).